

Publications et travaux communs réalisés dans le cadre du programme PNES « Cancers du poumon »

Liste des publications

1: Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. *Cancer*. 2010 Jun 1; 116(11):2682-7. PubMed PMID: 20336783.

2: Paliwal A, Vaissière T, Kraus A, Cuenin C, Cros MP, Zaridze D, Moukeria A, Boffetta P, Hainaut P, Brennan P, Herceg Z. Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. *Cancer Res*. 2010 Apr 1; 70(7):2779-88. Epub 2010 Mar 23. PubMed PMID: 20332232; PubMed Central PMCID: PMC2856323.

3: Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit JF, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A; EUELC Collaborators. EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. *Eur Respir J*. 2009 Dec; 34(6):1477-86. PubMed PMID: 19948914.

4: Paris C, Clement-Duchene C, Vignaud JM, Gislard A, Stoufflet A, Bertrand O, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P. Relationships between lung adenocarcinoma and gender, age, smoking and occupational risk factors: A case-case study. *Lung Cancer*. 2010 May; 68(2):146-53. Epub 2009 Jul 7. PubMed PMID: 19586681.

5: Clément-Duchêne C, Vignaud JM, Stoufflet A, Bertrand O, Gislard A, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P, Paris C. Characteristics of never smoker lung cancer including environmental and occupational risk factors. *Lung Cancer*. 2010 Feb; 67(2):144-50. Epub 2009 May 21. PubMed PMID: 19464070.

6: Vaissière T, Cuenin C, Paliwal A, Vineis P, Hoek G, Krzyzanowski M, Airoidi L, Dunning A, Garte S, Hainaut P, Malaveille C, Overvad K, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Trichopoulos D, Kaladidi A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Kumle M, Gonzalez CA, Martinez C, Dorransoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Hainaut P, Herceg Z. Quantitative analysis of DNA methylation after whole bisulfite amplification of a minute amount of DNA from body fluids. *Epigenetics*. 2009 May; 4(4):221-30. Epub 2009 May 24. PubMed PMID: 19458486.

7: Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P, Ferreira CG. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. *Cancer Lett*. 2009 Jun 28; 279(1):57-64. Epub 2009 Feb 13. PubMed PMID: 19217709.

8: Vaissière T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, Ferro G, Paliwal A, Hainaut P, Brennan P, Tost J, Boffetta P, Herceg Z. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. *Cancer Res*. 2009 Jan 1; 69(1):243-52. PubMed PMID: 19118009; PubMed

Central PMCID: PMC2613548.

9: Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpén F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martínez C, Bingham S, Rasmussen T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature*. 2008 Apr 3;452(7187):633-7. PubMed PMID: 18385738.

10: Veglia F, Loft S, Matullo G, Peluso M, Munnia A, Perera F, Phillips DH, Tang D, Autrup H, Raaschou-Nielsen O, Tjønneland A, Vineis P; Genair-EPIC Investigators. DNA adducts and cancer risk in prospective studies: a pooled analysis and a meta-analysis. *Carcinogenesis*. 2008 May;29(5):932-6. Epub 2008 Mar 14. PubMed PMID: 18343884.

11: Aranda M, Gonzalez-Nilo F, Riadi G, Díaz V, Perez J, Martel G, Hainaut P, Mimbacas A. Loss of TP53-DNA interaction induced by p.C135R in lung cancer. *Oncol Rep*. 2007 Nov;18(5):1213-7. PubMed PMID: 17914575.

12: Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. *Cancer Res*. 2007 Jun 15;67(12):5667-72. PubMed PMID: 17575133.

13: Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. *Oncogene*. 2010 Jun 28. [Epub ahead of print] PubMed PMID: 20581866.

14: Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C, Brambilla E. Telomere maintenance and DNA damage responses during lung carcinogenesis. *Clin Cancer Res*. 2010 Jun 1;16(11):2979-88. Epub 2010 Apr 19. PubMed PMID: 20404006.

15: Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. *J Thorac Oncol*. 2010 Apr;5(4):411-4. PubMed PMID: 20357614.

16: Brambilla E. Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. *Eur Respir J*. 2010 Apr;35(4):717-20. PubMed PMID: 20356981.

17: Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E, du Manoir S. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. *PLoS One*. 2010 Jan 29;5(1):e8960. PubMed PMID: 20126410; PubMed Central PMCID:

PMC2813300.

18: Ythier D, Brambilla E, Binet R, Nissou D, Vesin A, de Fraipont F, Moro-Sibilot D, Lantuejoul S, Brambilla C, Gazzeri S, Pedeux R. Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. *Lung Cancer*. 2009 Dec 3. [Epub ahead of print] PubMed PMID: 19962781.

19: Lin EH, Salon C, Brambilla E, Lavillette D, Szecsi J, Cosset FL, Coll JL. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer. *Cancer Gene Ther*. 2010 Apr;17(4):256-65. Epub 2009 Nov 6. PubMed PMID: 19893593.

20: Larrieu D, Ythier D, Binet R, Brambilla C, Brambilla E, Sengupta S, Pedeux R. ING2 controls the progression of DNA replication forks to maintain genome stability. *EMBO Rep*. 2009 Oct;10(10):1168-74. Epub 2009 Sep 4. PubMed PMID: 19730436; PubMed Central PMCID: PMC2759735.

21: Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2009 Sep;4(9):1049-59. PubMed PMID: 19652623.

22: Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. *Eur Respir J*. 2009 Jun;33(6):1485-97. PubMed PMID: 19483050; PubMed Central PMCID: PMC2762943.

23: Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee. The IASLC Lung Cancer Staging Project: data elements for the prospective project. *J Thorac Oncol*. 2009 Jun;4(6):679-83. Review. PubMed PMID: 19461401.

24: Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V, Cabon F, Brambilla C, Mehlen P, Bernet A. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. *J Natl Cancer Inst*. 2009 Feb 18;101(4):237-47. Epub 2009 Feb 10. PubMed PMID: 19211441.

25: Lantuéjoul S, Salameire D, Salon C, Brambilla E. Pulmonary preneoplasia--sequential molecular carcinogenetic events. *Histopathology*. 2009 Jan;54(1):43-54. Review. PubMed PMID: 19187179.

26: Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabrò E, Mancini A, Tosi D, Bossi P, Field JK, Brambilla E, Sozzi G; EUELC Consortium. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. *Am J Respir Crit Care Med*. 2009 Mar 1;179(5):396-401. Epub 2008 Dec 18. PubMed PMID: 19096006.

27: Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. *J Thorac Oncol*. 2008 Dec;3(12):1410-5. PubMed PMID: 19057265.

28: Ferté C, André F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. *Nat Rev Clin Oncol*. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20551944.

29: Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC. Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. *Ann Oncol*. 2010 Jun;21(6):1385-7. PubMed PMID: 20501506.

30: Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? *Ann Oncol*. 2010 May 23. [Epub ahead of print] PubMed PMID: 20497965.

31: Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2010 Jun 20;28(18):3076-83. Epub 2010 May 17. PubMed PMID: 20479403.

32: Raynaud CM, Mercier O, Dartevielle P, Commo F, Olausson KA, de Montpreville V, André F, Sabatier L, Soria JC. Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. *Clin Lung Cancer*. 2010 May;11(3):187-91. PubMed PMID: 20439195.

33: Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. *Ann Oncol*. 2010 Mar 15. [Epub ahead of print] PubMed PMID: 20231298.

34: Langer C, Soria JC. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. *Clin Lung Cancer*. 2010 Mar 1;11(2):82-90. Review. PubMed PMID: 20199973.

35: Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. *J Clin Oncol*. 2010 Mar 20;28(9):1527-33. Epub 2010 Feb 16. PubMed PMID: 20159815.

36: Kamal NS, Soria JC, Mendiboure J, Planchard D, Olausson KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, Le Chevalier T, Filipits M, Fouret P; International Adjuvant Lung Trial-Bio investigators. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. *Clin Cancer Res*. 2010 Feb 15;16(4):1206-15. Epub 2010 Feb 9. PubMed PMID: 20145178.

37: Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2010 Mar;5(3):369-75. PubMed PMID: 20090562.

38: Le Moulec S, Lorient Y, Soria JC. [Targeting KRAS pathway in NSCLC therapy]. *Bull Cancer*. 2009 Dec;96 Suppl:S69-74. French. PubMed PMID: 20034872.

39: Besse B, Vignot S, Soria JC. [Lung cancer: an update in 2010]. *Bull Cancer*. 2010 Jan;97(1):161-9. French. PubMed PMID: 20028651.

40: Planchard D, Lorient Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. *Semin Oncol*. 2009 Dec;36(6):553-65. Review. PubMed PMID: 19995647.

41: Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. *Crit Rev Oncol Hematol*. 2009 Nov 12. [Epub ahead of print] PubMed PMID: 19914087.

42: Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, Richon C, Dessen P, Lazar V, Soria JC, Kroemer G. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. *Oncogene*. 2009 Dec 3;28(48):4249-60. Epub 2009 Sep 14. PubMed PMID: 19749798.

43: Massard C, Tran Ba Loc P, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC. Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. *J Thorac Oncol*. 2009 Dec;4(12):1504-10. PubMed PMID: 19745763.

44: Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Darteville P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. *J Thorac Oncol*. 2009 Oct;4(10):1212-20. PubMed PMID: 19687761.

45: Lorient Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? *Nat Rev Clin Oncol*. 2009 Sep;6(9):528-34. Epub 2009 Jul 14. Review. PubMed PMID: 19597509.

46: Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. *J Thorac Oncol*. 2009 Sep;4(9):1126-35. PubMed PMID: 19574932.

47: Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann Oncol*. 2009 Oct;20(10):1674-81. Epub 2009 Jun 23. PubMed PMID: 19549709.

48: Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. *Ann Oncol*. 2009 Jul;20(7):1257-63. Epub 2009 Mar 17. PubMed PMID: 19297315.

- 49: Raynaud CM, Mercier O, Commo F, Darteville P, Gomez-Roca C, de Montpreville V, Sabatier L, Soria JC. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. *Lung Cancer*. 2009 Aug;65(2):144-9. Epub 2008 Dec 16. PubMed PMID: 19091442.
- 50: Mountzios G, Fouret P, Soria JC. Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers. *Nat Clin Pract Oncol*. 2008 Oct;5(10):610-8. Epub 2008 Jul 15. Review. PubMed PMID: 18628738.
- 51: Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. *Clin Cancer Res*. 2008 Jul 1;14(13):4096-102. PubMed PMID: 18593986.
- 52: Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in non-small-cell lung cancer. *N Engl J Med*. 2007 Oct 11;357(15):1559-61. PubMed PMID: 17928611.
- 53: Wild P, Bourgkard E, Paris C. Lung cancer and exposure to metals: the epidemiological evidence. *Methods Mol Biol*. 2009;472:139-67. Review. PubMed PMID: 19107432.
- 54: Pluquet E, Cadranet J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveira G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. *J Thorac Oncol*. 2010 Apr;5(4):491-6. PubMed PMID: 20195171.
- 55: Morère JF, Bréchet JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). *Lung Cancer*. 2010 Apr 16. [Epub ahead of print] PubMed PMID: 20400201.
- 56: Zalcman G, Bergot E. Gefitinib plus docetaxel in non-small-cell lung cancer. *Lancet*. 2009 Feb 14;373(9663):541; author reply 542. PubMed PMID: 19217981.
- 57: Bergot E, Levallet G, Zalcman G. [Genetic susceptibility for lung cancer and nicotinic addiction: toward a molecular explanation?]. *Rev Mal Respir*. 2008 May;25(5):519-22. French. PubMed PMID: 18535517.
- 58: Zalcman G, Bergot E, Hainaut P. Breast-cancer stromal cells with TP53 mutations. *N Engl J Med*. 2008 Apr 10;358(15):1635-6; author reply 1636. PubMed PMID: 18411429.
- 59: Bergot E, Richard N, Zalcman G. [Mechanisms of action of targeted therapies... and mechanisms of resistance]. *Rev Mal Respir*. 2007 Oct;24(8 Pt 2):6S180-7. Review. French. PubMed PMID: 18235412.

Abstracts et présentations orales

Les travaux du PNES ont fait l'objet de communications orales à l'ASCO, l'ESMO, l'EACR et l'IASLC.